⌕
Elicio Therapeutics · ELTX · Nasdaq
Tenet 43 · Weak
Compare
$1.50−5.66%At closeTenet 43 · Weak
$1.50−0.09 (−5.66%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Elicio Therapeutics (ELTX) Stock

Elicio Therapeutics (ELTX) closed at $1.50 on Nov 19, 2026; its Tenet Score is 43 of 100 against 474 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$1.50
Nov 19, 2026
Market cap
$45.0M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
1.25 – 16.00
low → high
Tenet Score
43/100
Weak · 474 Healthcare peers

Industry: Drugs · see every company filed here →

Elicio Therapeutics, Inc. scores 43/100. Weak. Strongest on value, quality is the soft spot versus 474 Healthcare peers. Insufficient inputs: Tenet 43 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=474
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
67
Quality
17
Health
46
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueCQualityFHealthDGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.4×
cap ÷ Sep 30, 2026 book value, Nov 18, 2026 close
P/S
—
no P/S on file
ROE
−315%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
3.43
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 1y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the…

Composite computed Nov 19, 2026 · peer basis: Healthcare (n=474) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 22 US ETFs · top wrappers by weightSee all ETFs holding ELTX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Elicio Therapeutics in?

Elicio Therapeutics is in the Healthcare sector and the Drugs industry.

What is Elicio Therapeutics' Tenet Score?

Elicio Therapeutics' Tenet Score is 43 out of 100, ranked against 474 Healthcare peers as of Nov 19, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.